Marinus Pharmaceuticals/MRNS

$9.77

-3.43%
-
1D1W1MYTD1YMAX

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of therapeutics for seizure disorders. The Company’s commercial product, ZTALMY (ganaxolone) oral suspension CV, has been approved by the United States Food and Drug Administration (FDA) for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase III trials in tuberous sclerosis complex and refractory status epilepticus. The Company's ganaxolone is a neuroactive steroid gamma-aminobutyric acid type A (GABAA) receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. Its ganaxolone is also being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
Ticker
MRNS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Scott Braunstein
Employees
151
Headquarters
Radnor, United States

MRNS Metrics

BasicAdvanced
$533.18M
Market cap
-
P/E ratio
-$2.64
EPS
0.94
Beta
-
Dividend rate

What the Analysts think about MRNS

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
107.78% upside
High $28.00
Low $9.00
$9.77
Current price
$20.30
Average price target

MRNS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-450.68% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$7.3M
21.67%
Net income
$-32.9M
3.13%
Profit margin
-450.68%
-15.23%

MRNS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.66%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.76
-$0.67
-$0.61
-$0.61
-
Expected
-$0.70
-$0.72
-$0.72
-$0.66
-$0.62
Surprise
9.09%
-7.31%
-14.89%
-7.66%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Marinus Pharmaceuticals stock

Buy or sell Marinus Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing